Theravance Biopharma

Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. It operates through the U.S. and Europe geographical segments. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Theravance Biopharma excels in Q2 with strong sales growth

Theravance Biopharma delivered strong financial performance in Q2 2024, driven by robust sales of YUPELRI and Trelegy.
While facing challenges such as ongoing losses and R&D expenses, the company remains focused on innovation and operational efficiency.
With a solid cash position, key patent grants, and growth opportunities in new markets, Theravance is poised for future growth and value creation.
Investors can look forward to potential milestones and market expansion initiatives as Theravance continues to execute its strategic vision.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Theravance Biopharma has pushed into congestion in 2023, backing and filling throughout the year. Its YUPELRI label offers targeted bronchodilation for COPD treatment, but isn't yet a long-term compounder. Collaboration revenues and YUPELRI sales are increasing, but the sentiment remains neutral and valuation is rich.

Theravance Biopharma: YUPELRI Numbers Don't Substantiate 9x Forward Sales, Rate Hold

DUBLIN , Aug. 28, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new ampreloxetine data in neurogenic orthostatic hypotension (nOH) will be presented at the 2023 International Congress of Parkinson's Disease and Movement Disorders (MDS), taking place August 27-31, 2023, in Copenhagen, Denmark. "The data presented at this meeting continue to support ampreloxetine's potential to deliver a consistent and durable benefit to MSA patients with nOH with a favorable safety and tolerability profile," said Roy Freeman, MBChB, Professor of Neurology, Director, Center for Autonomic and Peripheral Nerve Disorders, Beth Israel Deaconess Medical Center.

Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders

Thervance's (TBPH) second-quarter 2023 loss is narrower than expected. Revenues rise year over year.

Theravance's (TBPH) Q2 Earnings Beat Estimates, Revenues Miss

Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q2 2023 Earnings Conference Call August 7, 2023 5:00 PM ET Company Participants Rick Winningham - Chief Executive Officer Rhonda Farnum - Chief Business Officer Rick Graham - Head of Research and Development Aziz Sawaf - Chief Financial Officer Conference Call Participants David Risinger - Leerink Douglas Tsao - H.C. Wainwright Eva Xia Privitera - Cowen Operator Ladies and gentlemen, good afternoon.

Theravance Biopharma, Inc. (TBPH) Q2 2023 Earnings Call Transcript

Q2 2023 YUPELRI® (revefenacin) net sales of $55.0 million, recognized by Viatris, up 12% from Q2 2022 1 Q2 2023 YUPELRI total retail TRx and new to product TRx again reached all-time highs, up 26% and 53%, Y/Y, respectively2 PIFR-2 enrollment nearing completion; top-line data in late Q4 2023, with disclosure anticipated in January 2024 Company expects to complete $325 million capital return program by year-end, having returned $80.5 million via share repurchases during Q2 2023 and $263.8 million since inception through quarter end DUBLIN , Aug. 7, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced financial and operational results for the second quarter of 2023. "We are very encouraged by our team's performance in Q2, with YUPELRI achieving good growth in both the hospital and community settings over the prior year," said Rick E Winningham, Chief Executive Officer.

Theravance Biopharma, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update

DUBLIN , July 24, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its second quarter 2023 financial results and provide a business update after market close on Monday, August 7, 2023. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm IST) that day.

Theravance Biopharma to Report Second Quarter 2023 Financial Results on August 7, 2023

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?

Why Is Theravance Bio (TBPH) Down 3.8% Since Last Earnings Report?

DUBLIN , May 9, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) status to ampreloxetine for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA).  MSA is a rare neurodegenerative disorder in which patients suffer autonomic dysfunction affecting movement, balance, heart rate and blood pressure.

Theravance Biopharma, Inc. Announces Orphan Drug Designation Granted to Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy

Thervance's (TBPH) first-quarter 2023 loss wider than expected. Revenues decline year over year and also miss estimates.

Theravance's (TBPH) Q1 Earnings and Revenues Miss Estimates

Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q1 2023 Earnings Conference Call May 8, 2023 5:00 PM ET Company Participants Rick Winningham – Chief Executive Officer Rhonda Farnum – Chief Business Officer Rick Graham – Senior Vice President of Research and Development Aziz Sawaf – Chief Financial Officer Conference Call Participants David Risinger – SVB Securities Jingming Chen – Evercore Divya Rao – TD Cowen Operator Ladies and gentlemen, good afternoon. I'd like to welcome everyone to the Theravance Biopharma First Quarter 2023 Conference Call.

Theravance Biopharma, Inc. (TBPH) Q1 2023 Earnings Call Transcript

Q1 2023 YUPELRI® (revefenacin) net sales of $47.0 million, recognized by Viatris, up 8% from Q1 2022 1 Q1 2023 YUPELRI retail new patient starts and total prescriptions up 61% and 29%, respectively, year-over-year, reaching all-time highs2 CYPRESS Phase 3 study of ampreloxetine recruiting; anticipate completing enrollment during H2 2024 On track to complete $325 million capital return program by year-end; completed $215 million of share repurchases from inception through 4/30/23 Jim Kelly, Managing Director at Weiss Asset Management, joins Board of Directors DUBLIN , May 8, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced financial and operational results for the first quarter of 2023. "Through the beginning of 2023, we sharpened our commercial and development focus at Theravance, with YUPELRI retail new patient starts growing 61% and achieving a sixth consecutive quarter of record highs.

Theravance Biopharma, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

Theravance Biopharma has recently come under pressure from a reputable activist investor, Irenic Capital. The activist is pushing the company to initiate a large capital return and launch a strategic review.

Theravance Biopharma: Activist Pressure Might Lead To Substantial Capital Return

Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Theravance Biopharma (TBPH) Q1 Earnings Expected to Decline

DUBLIN , April 24, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2023 financial results and provide a business update after market close on Monday, May 8, 2023. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm IST) that day.

Theravance Biopharma to Report First Quarter 2023 Financial Results on May 8, 2023

NEW YORK--(BUSINESS WIRE)--Irenic Capital Management, LP (together with its affiliates, “Irenic” or “we”), a top shareholder of Theravance Biopharma, Inc. (NASDAQ: TBPH) (“Theravance” or the “Company”), today issued the following statement regarding the Company's appointment of Jim Kelly, Managing Director at Weiss Asset Management, to the Board of Directors (the “Board”): “Irenic welcomes the appointment of Jim Kelly to the Theravance Board.

Irenic Welcomes the Appointment of a Shareholder Representative to Theravance Biopharma's Board of Directors

DUBLIN , April 11, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced the appointment of Jim Kelly, Managing Director at Weiss Asset Management, the Company's second largest shareholder, to its Board of Directors. With the appointment of Mr.

Theravance Biopharma, Inc. Announces Appointment of Jim Kelly, Managing Director at Weiss Asset Management, to Board of Directors

Thervance's (TBPH) fourth-quarter loss wider than expected. Revenues decline year over year.

Theravance's (TBPH) Q4 Earnings and Revenues Miss Estimates

Theravance Biopharma Inc. (NASDAQ:TBPH ) Q4 2022 Results Conference Call February 27, 2023 5:00 PM ET Company Participants Rick Winningham - Chairman and Chief Executive Officer Rhonda Farnum - Senior Vice President, Chief Business Officer Rick Graham - Senior Vice President, Research and Development Aziz Sawaf - Chief Financial Officer Conference Call Participants David Risinger - SVB Securities Douglas Tsao - H.C. Wainwright Eva Privitera - Cowen Vikram Purohit - Morgan Stanley Liisa Bayko - Evercore ISI Operator Ladies and gentlemen, good afternoon.

Theravance Biopharma Inc. (TBPH) Q4 2022 Earnings Call Transcript

Theravance Bio (TBPH) delivered earnings and revenue surprises of -5% and 19.73%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Theravance Biopharma (TBPH) Reports Q4 Loss, Lags Revenue Estimates

Increases capital return program to $325 million from $250 million; as of 2/27/23, approximately $170 million remains in the program Discontinuing investments in research, reducing headcount by approximately 17% Reports highest quarter of YUPELRI® (revefenacin) net sales and profitability to date; $19.5 million Q4 2022 sales up 27% from Q4 2021 (TBPH implied 35% share)1 On track to begin enrollment in ampreloxetine Phase 3 study in Q1 2023 Appoints Susannah Gray to Board as new Independent Director Commits to declassify the Board of Directors DUBLIN , Feb. 27, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced financial results for the fourth quarter and full year ended December 31, 2022. The Company also announced three additional strategic actions to sharpen the Company's focus and deliver on its commitment to create shareholder value: Increased Capital Return Program to $325 million: Authorized a $75 million increase to the existing $250 million capital return program initiated in September 2022, bringing the total capital return program to $325 million.

Theravance Biopharma, Inc. Announces Strategic Actions and Reports Fourth Quarter / Full Year 2022 Financial Results and Business Update

NEW YORK--(BUSINESS WIRE)--Irenic Capital Management, LP, a top shareholder of Theravance Biopharma, Inc. (NASDAQ: TBPH), today released the below letter. *** February 27, 2023 Theravance Biopharma, Inc.

Irenic Sends Letter to Theravance Biopharma Regarding the Urgent Need for a Governance Overhaul, Capital Return and Strategic Review

Aurinia Pharmaceuticals

Cytokinetics

FibroGen

We look at a few drug/biotech companies, TBPH, FGEN, AUPH, CYTK, which are poised to beat on earnings in the fourth quarter.

4 Drug, Biotech Stocks Poised to Beat Q4 Earnings Estimates

DUBLIN , Feb. 21, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its fourth quarter and full year 2022 financial results and provide a business update after market close on Monday, February 27, 2023. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm GMT) that day.

Theravance Biopharma to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023

Theravance Bio (TBPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Theravance Biopharma (TBPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Strategic priorities focused on continued Net Sales growth for YUPELRI® (revefenacin) and conduct of the ampreloxetine Phase 3 study (CYPRESS) in Multiple System Atrophy (MSA) patients with symptomatic neurogenic orthostatic hypotension (nOH) Initiate CYPRESS study in Q1 2023 and submit orphan drug designation in early 2023 Complete PIFR-2 study for YUPELRI® in 2H 2023 Execute $250 million return of capital program, of which ~50% has been completed as of 12/31/2022 Achieve Non-GAAP 1 profitability by 2H 2023 DUBLIN , Jan. 9, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced its 2022 Accomplishments and 2023 Key Targets. "Last year was a transformative year for Theravance Biopharma and demonstrates the power of a team that leans into the Company's values and core purpose: delivering medicines that make a difference.

News for Theravance Biopharma Stock (TBPH)